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Abstract: 
Endothelial progenitor cells (EPCs) are a subtype of bone marrow–derived 
progenitor cells. Stromal cell-derived factor 1 (SDF-1)-mediated EPC mobilization 
from bone marrow to areas of ischemia plays an important role in angiogenesis. 
Previous studies have reported that advanced glycation endproducts (AGEs), which 
are important mediators of diabetes-related vascular pathology, may impair EPC 
migration and homing, but the mechanism is unclear. Syndecan-4 (synd4) is a 
ubiquitous heparan sulfate proteoglycan receptor on the cell surface, involved in 
SDF-1-dependent cell migration. The extracellular domain of synd4 (ext-synd4) is 
shed in the context of acute inflammation, but the shedding of ext-synd4 in response 
to AGEs is undefined. Here we investigated changes in ext-synd4 on EPCs in 
response to AGEs, focusing on the influence of impaired synd4 signaling on EPC 
migration and homing. We found decreased full length and increased residue of 
synd4 in cells incubated with AGEs, with concomitant increase in the soluble fragment 
of ext-synd4 in the cell medium. EPCs from patients with type 2 diabetes expressed 
less ext-synd4 as assessed by western blotting. Flow cytometry analysis showed less 
ext-synd4 on circulating CD34+ PMNCs, of which EPCs form a subgroup. We then 
explored the role of synd4 in EPC migration and homing. Impaired migration of 
synd4-deficient EPCs was observed by a 2D-chemotaxis slide. Furthermore, poor 
homing of synd4-/- EPCs was observed in a mouse model of lower limb ischemia. 
This study demonstrates that the shedding of synd4 from EPCs plays a key role in 
AGE-mediated dysfunction of EPC migration and homing. 
 
 
 
 
 
 
 
 
Introduction 
A growing body of evidence indicates that impaired collateralization and 
angiogenesis in diabetes mellitus (DM) contributes importantly to the risk of 
cardiovascular disease in this setting [1]. Endothelial progenitor cells (EPCs) are a 
subtype of bone marrow–derived progenitor cells expressing surface antigens of both 
hematopoietic stem cells and endothelial cells, which can mobilize from bone marrow 
to areas of ischemia to participate in angiogenesis [2]. In diabetic patients, impaired 
EPC homing is one of the major reasons why impaired formation of coronary 
collaterals occurs [3]. 
Stromal cell-derived factor-1 (SDF-1) is the most important chemokine involved in 
EPC homing, and exerts its effects through its classic receptor CXCR4 [4]. In 
response to tissue ischemia, a concentration gradient of SDF-1 is established and this 
induces EPC mobilization and homing to the ischemic area. Gallagher et al found that 
lack of SDF-1 secretion in the ischemic area contributes to EPC homing dysfunction, 
whilst administration of SDF-1 can promote wound healing, indicating that 
SDF-1-dependent signaling is critical for EPC homing [5].  
Recently, it has been reported that heparin sulfate proteoglycans (HSPGs) are 
required for cell adhesion, migration and proliferation triggered by the combination of 
cytokines with their receptors [6]. Syndecan4 (synd4), a member of the HSPG family, 
which is synthesized in most tissues, binds to various ligands comprising extracellular 
matrix growth factors and cytokines [7, 8]. Several lines of evidence have shown that 
synd4 is involved in the SDF-1/CXCR4 axis. Hamon et al reported that synd4 can 
form a complex with CXCR4 on HeLa cells, human primary lymphocytes and 
macrophages, thereby mediating SDF-1 signaling [9]. Another study demonstrated 
that synd4 of the surface of HeLa cells may function as another crucial receptor of 
SDF-1 to promote cell recruitment in addition to its classical receptor CXCR4 [10]. 
Although not verified directly, it is postulated that synd4-dependent signaling may also 
influence SDF-1-dependent migration and homing of EPCs. 
Synd4 contains an extracellular domain, a membrane-spanning region and an 
intracellular domain. Glycosaminoglycans are attached to the extracellular domain of 
synd4, through which synd4 mediates its extracellular signaling with heparan-binding 
growth factors [11]. Shedding of the extracellular domain of synd4 occurs 
constitutively and is accelerated under certain conditions, such as acute inflammation, 
trauma or mechanical stress [12-14]. A variety of chemokines and cytokines in acute 
inflammation can induce shedding of the extracellular domain of synd4 (ext-synd4) 
[12, 15, 16]. Oxidized fatty acids, which are pro-atherogenic, increase the release of 
synd4 into the medium of cultured arterial smooth muscle cells [17]. However, little is 
known about the fate of ext-synd4 in response to modified biomolecules that 
accumulate in DM.  
Advanced glycation endproducts (AGEs) are a heterogeneous group of molecules 
formed from the nonenzymatic reaction of reducing sugars with free amino groups of 
proteins, lipids, and nucleic acids. These accumulate in DM, and are believed to be 
important pathogenetic mediators of many complications of diabetes, even where 
glycemic control is good [18]. Our previous work and that of others suggest that AGEs 
impair EPC function, though the mechanism of this has not been properly elucidated 
[19-21]. This study was designed to explore the effect of AGEs on ext-synd4 shedding 
from the surface of EPCs, as well as to examine whether loss of its extracellular 
domain from the cell surface may lead to impairment of synd4-dependent signaling. 
We especially focused on the influence of impaired synd4 signaling on EPC migration 
and homing. Our findings suggest synd4 signaling dysfunction as a novel mechanism 
for impaired EPC homing in DM.  
 
Methods： 
Animals and Experimental Protocol: 
    All procedures with animals and cell culture were approved by the Institutional 
Ethics Committee of Nanjing Drum Tower Hospital (Approval No. 20011141) and 
performed in accordance with the guidelines set forth in the Guide for the Care and 
Use of Laboratory Animals published by the National Institutes of Health (National 
Institutes of Health publication No. 85-23, revised 1985). C57BL/6 mice were 
purchased (8 weeks of age) from the Model Animal Research Center of Nanjing 
University. Synd4 -/- mice were purchased from CARD Kumanoto University, and bred 
at the Model Animal Research Center of Nanjing University. Age-matched C57BL/6 
mice served as controls. Animals were fed a standard laboratory diet with free access 
to food and water, and kept in a temperature- and humidity (65%–70%)-controlled 
room (22°C + 1°C), with a 12:12 hour light/dark cycle. After study, all animals were 
euthanized by cervical dislocation under ether anesthesia.  
 
Cell Isolation and Culture: 
Human late EPCs were harvested from peripheral blood samples as described 
previously [20] and cultured with EGM-2 medium supplemented with growth factors 
and serum (EGM2 bulletkit, USA). Cells were confirmed by as late EPCs by flow 
cytometric analysis, Dil-acLDL uptake and tube formation assay. Detailed description 
of cell isolation and culture are provided in the online-only Data Supplement. 
 
Treatment of Late EPCs with AGEs and Analysis for Synd4 
   Late EPCs were seeded on 6-well plates and serum starved overnight in 1% FBS. 
Cells were incubated with different concentrations of AGEs (Calbiochem, Germany) 
for two time periods (12 h and 48 h). Control cells were treated with bovine serum 
albumin (BSA) without glycation. Incubation concentrations and times giving the 
greatest effect were used in later experiments. To determine synd4 content, cells were 
scraped and lysed, and whole-cell lysates were treated with heparan 
sulfate-degrading enzymes as described [22]. Samples were separated by sodium 
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and were blotted 
onto polyvinylidene fluoride membranes. The membranes were blocked in 5% BSA 
for 1 h before overnight incubation at 4°C with primary antibodies to synd4 (rabbit 
anti-synd4 against the cytoplasmic domain of synd4, Bioworld, USA; goat anti-synd4 
against the extracellular domain of synd4, LifeSpan BioSciences, USA), as well as to 
β-actin (rabbit anti-β-actin, Bioworld, USA) to confirm loading of comparable amounts 
of protein in each lane. Membranes were then incubated with horseradish 
peroxidase–conjugated secondary antibodies for 1 h. The amount of synd4 was 
determined using enhanced chemiluminescence and densitometry.  
 
Late EPC treatment and western blotting  
   Cells were treated with N-acetylcysteine (NAC; 10mM, Sigma, USA) to inhibit 
oxidative stress, and receptor for AGE (RAGE) was blocked using antibody to RAGE 
(1:100, BD, USA). Level of reactive oxygen species (ROS) in EPCs was evaluated by 
DCFH-DA assay (Sigma, USA) according to the manufacturer’s instructions. Cells 
were stimulated with SDF-1 (10ng/ml; Perprotech, USA). AMD3100   (5ug/ml; 
Calbiochem, Germany) was used to inhibit CXCR4. Cells were lysed, proteins 
extracted and separated by SDS-PAGE, and protein loading was confirmed by 
Coomassie blue staining. β-actin was used as loading control. Primary antibodies 
used were anti-synd4 (1:500,Lifespan, USA), anti-Akt (1:1000, CST, USA), anti-p-Akt 
(473) (1:500, CST, USA), anti-eNOS (1:1000, BD Biosciences, USA), anti p-eNOS 
(1:100, BD Biosciences, USA), and anti-β-actin (1:1000, Bioworld, China). Detailed 
descriptions are provided in the online-only Data Supplement.  
 
CD34+ Peripheral Blood Mononuclear Cell (PMNC) Isolation and Flow Cytometric 
Analysis 
    The clinical study followed the principles of the Declaration of Helsinki and was 
approved by the Institutional Ethics Committee of Nanjing Drum Tower Hospital 
(Approval No. 20011141). Written informed consent was obtained from all enrolled 
patients. A total of 25 patients with type 2 DM (T2DM) and 25 age- and sex-matched 
healthy subjects as controls were enrolled. T2DM was diagnosed as HbA1c level ≥ 
6.5% or fasting plasma glucose ≥ 7.0 mmol/L or 2 h plasma glucose ≥ 11.1mmol/L 
during an oral glucose tolerance test. Baseline clinical characteristics of each 
participant were collected, including age, sex, fasting blood glucose and HbA1c. 
CD34+ peripheral blood mononuclear cells (PMNCs) were isolated from blood using a 
CD34 MicroBead Kit according to the manufacturer's protocol (Miltenyi Biotec, 
Germany). The cells were labeled with anti-synd4 (1:25,Lifespan,USA) and Dylight 
488 Goat Anti-Rabbit IgG secondary antibody (1:100,Earthox,USA ). Isotype-identical 
fluorescent secondary antibody served as negative controls. Cells were then 
analysed by flow cytometry (FACSCalibur, Becton Dickinson, USA) and Cell Quest 
Software counting 10,000 events per sample. 
 
Stable Knockdown and Silencing Experiments 
   Lentivirus for stable shRNA integration into the host genome was purchased from 
Shanghai Genechem Co, Ltd. Target sequence for human Sdc4 was 5_- 
TGATCCTACTGCTCATGTA -3_. To achieve stable knockdown, late EPCs seeded on 
6-well plates were transduced at 70%-80% confluence with lentivirus carrying a synd4 
shRNA (Lv si-synd4) sequence or null (Lv null). Lentivirus also carried the 
puromycin-resistance and green fluorescent protein (GFP) genes. Cells were infected 
for 6 h in medium without serum, following which the medium was replaced with 
complete medium. Puromycin (1μg/ml) was added to cells 48 hours after infection and 
selection occurred over 3 days. The cells were identified by CD45-/CD34+/KDR+. The 
inhibition efficiency were verified by western blot analysis (Supplemental Fig. 1). Cells 
were then used in the chemotaxis assay, as previously reported [23]. Detailed 
descriptions are provided in the online-only Data Supplement. 
 
Cell Preparation and Transplantation 
   Mouse EPCs were harvested from femurs and tibias of C57BL/6 and synd4-/- 
mice as described previously [5], and cultured with EGM-2 medium (EGM2; Lonza, 
USA) supplemented with murine vascular endothelial growth factor (10ug/L; VEGF; 
Peprotech) and 10% fetal bovine serum (FBS; Gibco, USA). Cell identity was 
confirmed by flow cytometric analysis and Dil-acLDL uptake (Supplemental Fig. 2), 
and cells were labeled with the lipophilic fluorochrome chloromethyl benzamidodialkyl 
carbocyanine (CM-DiI, Molecular Probes) according to the manufacturer’s 
instructions. A mouse model of critical limb ischemia was established as described 
previously [19], and mice with limb ischemia were injected with 5x106 EPCs via 
neighboring normal tissue. Two weeks after EPC transplantation, animals were 
euthanized and histological analysis was undertaken to assess EPC homing and 
angiogenesis. Detailed descriptions are provided in the online-only Data Supplement. 
 
Statistics  
   SPSS 16.0 was used for all statistical analyses. Data are presented as 
mean±SEM of three independent experiments unless otherwise stated. The 
significance of changes was evaluated using analysis of variance and Tukey’s 
post-hoc test. Values of P<0.05 were considered statistically significant. 
 
Results: 
Characterization of Late EPCs 
Late EPCs isolated from human blood samples were proliferated in culture. 
Dil-acLDL uptake assay was used to further confirm the EPC phenotype. After 
co-culture with Dil-acLDL, the cells were positive for DiI-acLDL and concomitant BS-1 
lectin (Fig.1A). Flow cytometric analysis showed these cells to be positive for KDR 
(84.4%) and CD34 (51.2%), and negative for CD45 (0.11%) (Fig.1B). Then, these 
cells showed tube formation on matrigel (Fig.1C). Taken together, these data show 
the cells in these culture conditions to be predominantly late-stage EPCs. 
 
Shedding of Ext-Synd4 is accelerated in late EPCs following incubation with 
AGEs.  
We determined whether late EPC incubation with AGEs accelerated shedding, 
and decreased cell surface protein level of ext-synd4. EPCs were cultured and 
incubated with different concentrations of AGEs (50, 100, 200, 400 μg/ml) for 12 h. 
Synd4 was detected by western blotting using an antibody against an extracellular 
epitope. Results showed that the expression of ext-synd4 on cells decreased as the 
concentration of AGEs increased, with the most effective concentration being 200 
μg/ml (Fig.2B). Furthermore, when the stimulation time was extended to 48h, similar 
result about ext-synd4 decrease on cells was observed (Fig.2C). Next, we used 
ELISA to measure soluble synd4, which was shedded from cells in the conditioned 
medium. We found that, after 12 h stimulation, soluble synd4 in the medium of treated 
cells increased by 30% compared with control (Fig.2D). These results indicated that 
synd4 was shedded from HUVECs, contributing to increased protein level in the 
medium and decreased on cell surface. 
Furthermore, we detected synd4 by western blot using an antibody against a 
cytoplasmic epitope. As previously reported [22], the synd4 fragment of about 10 kDa 
represented the residual fragment that constituted the cellular part of synd4 after 
shedding. Meanwhile, the fragment of about 40 kDa represented full length protein. 
Full length synd4 (about 40 kDa) decreased after AGE treatment. Concomitantly, the 
fragment about 10kDa was found to be increased after AGEs administration (Fig.2E). 
These data demonstrate that shedding of ext-synd4 is accelerated in response to 
AGEs, giving rise to decreased expression of ext-synd4 on the cell surface.  
 
RAGE and ROS are Involved in AGE-Dependent Ext-synd4 Shedding. 
As shown in Fig 2B and C, ext-synd4 shedding induced by AGEs occurred in a 
dose-dependent manner, with a maximum effect seen at 200 μg/ml concentration, 
consistent with a receptor-mediated effect. The multi-ligand receptor for advanced 
glycation end products (RAGE) was the first, and has been the most studied, receptor 
for AGEs. To investigate whether the mechanism of synd4 shedding involved RAGE, 
it was blocked using a blocking antibody (anti-RAGE) and ext-synd4 was measured 
by western blotting. We found that ext-synd4 shedding induced by AGEs was largely 
but not completely inhibited by anti-RAGE (Fig.2F). The metabolic derangements in 
DM enhance production of ROS and trigger pro-inflammatory signaling. We 
postulated that ext-synd4 shedding would likely be regulated by ROS level. We used 
NAC to inhibit oxidative stress in cells, and found that shedding of ext-synd4 induced 
by AGEs could be rescued in the presence of NAC. ROS levels in cells were tested 
using DCFH-DA. We found that AGEs significantly increased ROS by late EPCs, 
whilst in the presence of NAC or of anti-RAGE ROS generation was decreased 
(Fig.2G). The shedding of ext-synd4 was positively associated with ROS level. These 
data suggest that the shedding of ext-synd4 may be accelerated through 
AGE/RAGE/ROS signaling. 
 Ext-synd4 on the Surface of Late EPCs and PMNCs is Decreased in T2DM 
Patients 
As above, we found decreased ext-synd4 on the surface of late EPCs following 
incubation with AGEs in vitro. We went on to explore the level of ext-synd4 on the 
surface of late EPCs in patients with T2DM (Supplemental Tab 1). Late EPCs were 
isolated from T2DM patients. Following lysis of the cells, we detected and measured 
ext-synd4 by western blotting. We found ext-synd4 to be significantly decreased in 
late EPCs from T2DM patients compared with those from control subjects (Fig.3A).  
We also wished to specifically determine surface expression of ext-synd4 on 
circulating late EPCs. In view of the sparsity of CD34+/KDR+ cells in peripheral blood, 
we analyzed circulating CD34+ PMNCs, of which EPCs form a subgroup, by flow 
cytometry. We found that surface ext-synd4 on circulating CD34+ PMNCs was 
decreased in T2DM (Fig.3B).  
Taken together, these data demonstrate that AGEs induce reduction of ext-synd4 
expression on the surface of EPCs in T2DM owing to increased shedding. 
 
Synd4 Regulates Late EPC migration.  
To verify the function of synd4 in late EPC migration, synd4 was specifically 
down-regulated using RNAi. Late EPCs were transduced with Lv si-synd4 or Lv null. 
Specific RNAi decreased synd4 protein synthesis by ～60%. Lv null-transduced late 
EPCs were also incubated with AGEs or control. Chemotaxis assay revealed that 
cells of all groups moved along an SDF-1 (0-5ng/ml) gradient. Forty cells of each 
group were selected randomly and the movement of the cells was tracked (Fig.4A). All 
the cells in the three groups were moved in a chemotactic gradient. The p-value of the 
Rayleigh test in logarithmic scale was below 0.05. Synd4 knockdown in late EPCs 
significantly reduced the cell migration, similar to the movement of cells incubated 
with AGEs. The euclidean and cumulative distances were decreased in synd4 
deficiency and AGEs treated EPCs, compared with WT EPCs, suggesting defective 
motility, (Fig.4A, B and C, and Supplemental Videos). 
It has previously been demonstrated that SDF-1 is the critical chemokine for EPC 
homing [24]. We explored the role of synd4 in SDF-1-dependent EPC homing. The 
siRNA was used to decrease synd4 expression (Fig.4F). CXCR4 and CXCR7 were 
two receptors of SDF-1 on the EPCs surface. SDF-1 could induce CXCR4 
internalization and CXCR7 externalization. Synd4 knockdown and lenti-virus 
treatment had no effect on CXCR4 and CXCR7 alternation in the late EPCs (Fig. 4D 
and E). We found that SDF-1 stimulation of late EPCs induced both Akt and eNOS 
phosphorylation (an index of their activation). Synd4 down-regulation could blunt 
SDF-1-induced phosphorylation of both Akt and eNOS (Fig.4G and H). Since CXCR4 
has been reported as the classical receptor for SDF-1, we used AMD3100 to inhibit 
CXCR4, and found that SDF-1-induced Akt and eNOS phosphorylation were also 
decreased (Fig.4G and H). The reduction of Akt and eNOS phosphorylation was not 
different in cells with synd4 knockdown compared with cells treated with AMD3100. 
However, when synd4 and CXCR4 were abrogated simultaneously, both Akt and 
eNOS phosphorylation were further reduced compared with cells with synd4 
deficiency or AMD3100 treatment alone. These data indicate that synd4 may act as 
an independent receptor to regulate SDF-1-dependent EPC migration. 
 
Synd4 is Necessary for Late EPC Homing 
Since we found synd4 could mediate EPC migration in cultured cells, we next 
established a lower limb ischemic model, to investigate whether lack of synd4 would 
impair EPC homing. BM-derived EPCs was isolated from synd4-deficient mice. EPCs 
from corresponding wild-type (WT) mice were used as control. EPCs without synd4 
revealed similar CXCR4 expression, poor migration and decreased eNOS 
phosphorylation compared with WT EPCs (Supplemental Fig. 3). EPCs tagged with 
CM-Dil were injected into the ischemic lower limb through neighboring normal tissue. 
Fluorescence analysis showed that the number of EPCs homing to the site of injury in 
synd4-deficient mice was considerably lower than that in controls (Fig.5A). To clarify 
whether EPC homing had an effect on angiogenesis in ischemic tissue, we labeled 
vessels with CD31 and vWF. Fluorescence analysis indicated that the vascular 
density in mice injected with WT EPCs was higher than in mice injected with 
synd4-deficient EPCs (Fig.5B and C). Meanwhile, we assessed immune cell in the 
ischemic tissue by immunoflurecence with CD45. No difference of CD45 positive cell 
was observed among three groups (Supplemental Fig. 4). These data demonstrate 
that synd4 plays an essential role in EPC homing for wound healing and vessel 
formation in vivo. 
 
Discussion 
The current study was designed to dissect the role of synd4 in EPC migration and 
homing in the presence of AGEs. The four main findings were as follows: (1) The 
shedding of ext-synd4 on EPCs was accelerated by AGEs. (2) Ext-synd4 was 
decreased on the surface of EPCs following prolonged exposure to AGEs. (3) Synd4 
deficiency impaired SDF-1-dependent EPC migration. (4) Synd4 deficiency impaired 
EPC homing. It was likely that deficiency of ext-synd4 on the surface of EPCs as a 
result of sustained shedding in response to AGEs may be partly responsible for the 
impairments in both EPC homing and angiogenesis in DM.  
Various agents can induce synd4 shedding in the context of, for example, acute 
injury, wound healing and atherosclerosis [12, 14, 16, 17, 22, 25]. Normally, syndecan 
shedding occurs through direct proteolysis (e.g. thrombin) or receptor-mediated 
activation of sheddases (e.g. epithelial growth factors). It is still not fully clear how 
extracellular stimuli influence sheddases to mediate syndecan cleavage. Different 
stimuli appear to activate distinct intracellular signaling pathways, and increased 
oxidative stress is thought to play an important role in sheddase activation and 
syndecan shedding [26, 27]. AGEs are a complex and heterogeneous group of 
abnormal metabolic compounds that accumulate in DM. Here, we demonstrated for 
the first time that AGEs could induce synd4 shedding, and reported that increase in 
ROS, induced by AGEs, played a part in the process of shedding.   
We found that soluble ext-synd4 in the conditioned medium increased, and cell 
surface ext-synd4 reduced, 12 h after incubation with AGEs. Western blotting using 
an antibody recognizing a cytoplasmic epitope of synd4 (cyt-synd4) demonstrated a 
10 kDa fragment, representing the residual cellular part of synd4 after shedding, in 
cells treated with AGEs. When AGE incubation was prolonged to 48h, the expression 
of ext-synd4 was still decreased. Similar results regarding synd4 turnover have been 
reported by Strand et al [22]. In their study, pro-inflammatory cytokines, including 
TNF-, IL-1β and lipopolysaccharide, were used to treat myocytes and fibroblasts; 
western blotting showed the presence of a 10kDa fragment as detected by antibody 
against cyt-synd4, while nothing was detected using antibody against ext-synd4, 
suggesting that ext-synd4 was decreased on the cell surface due to shedding. 
Ext-synd4 expression depends on the balance between synd4 synthesis and 
shedding. Ramnath et al. found that synd4 mRNA of ECs significantly increased 1 h 
after stimulation with TNF-α and decreased to normal after 24 h [28]. Extrodomain 
shedding paralleled synd4 synthesis initially, but was more sustained and greater in 
magnitude later on, suggesting that the compensatory synthesis of synd4 may not 
catch up with the speed of consumption, giving rise to ext-synd4 deficiency following 
persistent stimulation. In this study, residual cellular part of synd4 was increased after 
AGEs treatment, indicating increased synd4 gene expression. Meanwhile full length 
and extracellular epitope of synd4 were decreased, indicating more sustained and 
greater extracellular epitope shedding induced by AGEs. 
Besides synd4, syndecan 1 (synd1), another member of the syndecan family, 
was reported to be decreased on the cell surface in response to inflammation. In a pig 
ischemia/reperfusion model, the extrodomain of synd1 (ext-synd1) and other heparan 
sulfates were shedded, resulting in aberrant endothelial heparan sulfate expression 
[29]. In another study, the content of ext-synd1 was found to be decreased in the 
vasculature of doxorubicin-treated hearts [30]. When lipopolysaccharide was used to 
induce sepsis in rats, decreased ext-synd1 together with up-regulated matrix 
metalloproteinases 2 and 9 were observed in aortic homogenates [31]. We therefore 
propose that synd4 and other syndecan family members are highly sensitive to 
proteolytic degradation and shedding under inflammatory conditions, and when such 
conditions persist, the extrodomain of these proteins decrease on the cell surface, 
resulting in altered cell phenotype.  
Several studies have reported that ext-synd4 can bind SDF-1 directly to mediate 
SDF-1-dependent cell migration [9, 10]. Whether ext-synd4 shedding contributes to 
impaired EPC migration in response to SDF-1 has not been known. Here we 
observed that cell migration in an SDF-1 gradient was impaired in parallel with loss of 
ext-synd4 from the surface of EPCs in response to AGEs, and this phenotype was 
reproduced in cells by genetic ablation of synd4. We also found that 
SDF-1-dependent signaling pathways were impaired in synd4-deficient cells. These 
results indicated that loss of ext-synd4 alters synd4-dependent cell migration.  
SDF-1 plays an important role in the mobilization of cells from the bone marrow 
and may also regulate the mobilization and recruitment of EPCs [4]. The biological 
effect of SDF-1 was reported to depend mainly on CXCR4, a specific G 
protein-coupled receptor [32]. Synd4 was shown to bind directly with SDF-1, and form 
a heteromeric complex with CXCR4 at the plasma membrane of cells [9]. 
Glycosaminoglycans (GAGs) binded SDF-1 and facilitated the binding of SDF-1 to 
CXCR4. When GAGs were blocked by β-D-xyloside, cell chemotaxis induced by 
SDF-1 was found to be decreased significantly [33]. Another study reported that the 
cytoplasmic tail of synd4 played an important role in SDF-1-mediated signal 
transduction. SDF-1 can induce synd4 tyrosine phosphorylation, which was 
co-associated with tyrosine phosphorylated CXCR4 [10]. In our study, we observed 
SDF-1 downstream signaling activation was suppressed by either down-regulation of 
synd4 or inhibition of CXCR4. Combined synd4 silencing and CXCR4 inhibition was 
found to have a synergistic effect on SDF-1 signaling. Our data suggested that synd4 
behaves as an SDF-1 receptor to mediate EPC migration. 
 
Conclusion: 
This study provides evidence for the first time that AGEs induce accelerated 
shedding of ext-synd4, which in turn leads to impaired EPC migration and homing. 
Our findings suggest that decreased ext-synd4 on the EPC surface is a novel 
mechanism by which AGEs induce EPC homing dysfunction. 
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Figure legend: 
Figure 1. Late EPCs are identified by flow cytometry and Dil-acLDL uptake assay. (A) 
Dil-acLDL uptake assay shows the cells were positive for DiI-acLDL and concomitant 
BS-1 lectin. N=3. Bar: 25um. (B) Flow cytometric analysis reveals the cells, isolated 
from human blood sample, are positive for KDR and CD34, and negative for CD45. (C) 
Representative image showing tube formation of late EPC in matrigel. N=3. Bar: 
100um. 
 
Figure 2. AGEs induce synd4 shedding from late EPCs. (A) Schematic showing the 
two antibodies against the extracellular domain and cytoplasmic epitope of synd4. (B 
and C) Representative immunoblots and quantitative data showing ext-synd4 level in 
late EPCs following 12 h (B) or 48 h (C) incubation time with different concentrations 
of AGEs using antibody against ext-synd4. (D) Soluble ext-synd4 levels in the cell 
culture medium were measured by ELISA. (E) Representative immunoblots and 
quantitative data showing cyt-synd4 protein expression in late EPCs incubated with 
200 μg/l AGEs for 12 h using antibody against cyt-synd4. The fragment of about 10 
kDa was increased, representing the residual fragment of synd4 after shedding; in 
parallel, the full length fragment (40 kDa) of synd4 was decreased. (F) Representative 
immunoblots and quantitative data showing that the decrease in ext-synd4 in late 
EPCs following AGEs incubation was attenuated in the presence of anti-RAGE 
antibody or N-acetylcysteine (NAC). (G) Fluorescence intensity and quantitative data 
showing that the ROS level in late EPCs was increased after AGEs incubation, and 
decreased when anti-RAGE antibody or NAC was co-incubated. Original 
magnification, ×200. N=3. *, p<0.05, compared with the group incubated with BSA; #, 
p<0.05, compared with the group incubated with AGEs. 
 
Figure 3. Ext-synd4 is diminished on late EPCs and CD34+ PMNCs from patients with 
T2DM. (A) Representative immunoblots and quantitative data showing that ext-synd4 
expression was decreased in late EPCs from T2DM patients compared with those 
from controls. N=6. (B) Representative flow cytometric and quantitative data showing 
that surface ext-synd4 expression was decreased in CD34+ PMNC from T2DM 
patients compared with those from controls. N=6, *, p<0.05, compared with the control 
group. 
 
Figure 4. Inhibition of synd4 reduces the migration of late EPCs. Late EPCs were 
treated with Lv null, Lv si-synd4, or Lv null together with AGEs, and their migration 
was examined. (A) Movements of the three groups of late EPCs in an SDF-1 gradient 
(0-5 ng/ml) were observed simultaneously by fluorescence microscopy. Forty cells of 
each group were selected randomly, tracked and analyzed. The quantitative 
evaluation of cumulative (B) and Euclidean (C) distances is displayed in the lower 
panels. (D and E) Representative immuno-fluorescence and quantitative data 
revealed that SDF-1 induced CXCR4 internalization and CXCR7 externalization. No 
alternation of CXCR4 and CXCR7 was observed when synd4 was down-regulated. (F 
to H) Representative immunoblots and quantitative data revealing the downstream 
pathways induced by SDF-1 in late EPCs. Synd4 expression was suppressed by Lv 
si-synd4 treatment (F). SDF-1 induced phosphorylation of Akt and eNOS, which was 
blunted by synd4 deficiency and/or incubation with AMD3100 (G and H). *, p<0.05, 
compared with the group of Lv null. #, p<0.05, compared with the group of SDF-1. &, 
p<0.05, compared with the corresponding control. Bar=50um, MFI: mean 
fluorescence intensity. 
 
Figure 5. Synd4 deficiency blunts EPCs homing. (A) Representative fluorescence 
microscopy and quantitative data showing impaired EPC homing into ischemic lower 
limb through neighboring normal tissue. (B) Representative fluorescence microscopy 
and quantitative data revealed that CD31 positive vascular density was decreased in 
animals injected with synd4-deficient EPCs compared to those injected with wild-type 
(WT) EPCs. (C) Representative fluorescence microscopy and quantitative data 
showing that vWF positive vascular density was decreased in animals injected with 
synd4-deficient EPCs compared to those with WT EPCs. N=6, Bar=100um in A, 50um 
in B and 200um in C, *, p<0.05, compared with the corresponding control.  
Graphical Abstract: 
AGEs induce syndecan 4(synd4) shedding from late EPCs. The synd4 was an 
important receptor on the cell surface to mediate cell migration. (A) Schematic 
showing the antibody against the cytoplasmic epitope of synd4. (B) Representative 
immunoblots showing synd4 expression in late EPCs incubated with 200 μg/l AGEs 
for 12 h using antibody against cyt-synd4. The fragment of about 10 kDa was 
increased, representing the residual fragment of synd4 after shedding; in parallel, the 
full length fragment (40 kDa) of synd4 was decreased. N=3. (C) Representative flow 
cytometric showing that surface ext-synd4 expression was decreased in CD34+ 
PMNC from T2DM patients compared with those from controls. N=6. (D) Late EPCs 
were treated with Lv null, Lv si-synd4, or Lv null together with AGEs, and their 
migration was examined in an SDF-1 gradient (0-5 ng/ml) by fluorescence microscopy. 
Forty cells of each group were selected randomly, tracked and analyzed. Inhibition of 
synd4 reduces the migration of late EPCs. N=3. 
 
